Greenland Mines Ltd GRML
Mines"), formerly known as Klotho Neurosciences, Inc., develops essential medicines for the treatment of chronic diseases –
cancer, cardiovascular, and neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio
and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which
uses a gene therapy approach to introduce a therapeutic protein called "Klotho" inside the body to treat neurodegenerative
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D | $634.2K | $0 | $0 | — | — |
| SG&A | $3.1M | $2.8M | $30.5K | $534.0K | — |
| Total operating expenses | $7.1M | $5.5M | $631.3K | $153.1K | — |
| Operating income | -$7.1M | -$5.5M | -$631.3K | -$657.0K | — |
| Interest expense | $2.3M | $356.6K | $76.2K | — | — |
| Pre-tax income | -$10.6M | -$6.2M | -$707.5K | $1.6M | — |
| Income tax | — | — | $690.6K | $322.0K | — |
| Net income | -$10.6M | -$6.2M | -$707.5K | $1.2M | — |
| EPS, basic | -0.22 | -0.32 | -0.05 | — | — |
| EPS, diluted | -0.22 | -0.32 | -0.05 | — | — |
| Shares, diluted (wtd. avg.) | 48.5M | 19.2M | 15.1M | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cash and equivalents | $7.2M | $63.7K | $2.8K | $75.9K | $5.0K |
| Total current assets | $7.3M | $157.8K | $6.6K | $440.2K | $5.0K |
| Total assets | $9.6M | $2.5M | $2.2M | $118.2M | $5.0K |
| Accounts payable | $44.6K | $63.7K | $151.3K | — | — |
| Short-term debt | — | — | — | $300.0K | — |
| Total current liabilities | $76.8K | $1.2M | $1.6M | $506.2K | $8.5K |
| Total liabilities | $129.8K | $1.3M | $1.6M | $4.9M | $8.5K |
| Retained earnings | -$21.1M | -$10.6M | -$3.9M | -$4.0M | -$3.6K |
| Total equity | $9.5M | $1.2M | -$442.7K | -$4.0M | -$3.6K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$5.9M | -$2.9M | -$446.9K | -$493.0K | — |
| Stock-based compensation | $1.6M | $2.6M | — | — | — |
| Investing cash flow | — | -$123.5K | $23.9K | -$116.2M | — |
| Financing cash flow | $13.0M | $3.1M | $350.0K | $117.0M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-090213.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Net income | — | $1.2M | -$707.5K | -$6.2M | -$10.6M |
Recent filings and events
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Acquisition or disposal completed A purchase or sale of a significant business or asset has closed. Item 2.01
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Material agreement signed Item 1.01
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Material agreement signed Item 1.01
- Shareholder vote Item 5.07
- Material agreement signed Item 1.01
- Shareholder rights changed The terms attaching to the shares themselves have changed. Item 3.03
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $237.48B | 30.9x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $193.48B | 23.0x | 2.4% |
| MRNA | Moderna, Inc. | $79.89B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $40.08B | — | — |
| BIIB | BIOGEN INC. | $37.01B | 28.5x | 2.2% |
| EXEL | EXELIXIS, INC. | $15.99B | 23.2x | 7.0% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $14.51B | 30.6x | 21.4% |
| HALO | HALOZYME THERAPEUTICS, INC. | $14.26B | 49.1x | 37.6% |